Identifying drugs needing pharmacogenetic monitoring in a Korean hospital

American Journal of Health-System Pharmacy

Volumn 64, Issue 2, 2007, Pages 166-175

  Kim, Young Mi ^a   Yoo, Seung Hee ^a   Kang, Rae Young ^a   Kim, Min Jung ^a   Bae, Yoon Young ^a   Lee, Yeon Kyung ^a   Jeon, Su Jin ^a   Chon, Kung Ju ^a   Shin, Sang Mi ^a   Kim, Sang Geon ^a   Park, Kyoung Ho ^a   Son, In Ja ^a  

^a Seoul National University Hospital   (South Korea)

Author keywords

Amitriptyline; Anticonvulsants; Antidepressants; Antidiabetic agents; Anxiolytics, sedatives and hypnotics; Asians; Codeine; Decision making; Diazepam; Glimepiride; Hospitals; Metabolism; Methodology; Nortriptyline; Opiates; Oxycodone; Pharmacogenetics; Polymorphism

Indexed keywords

ACECLOFENAC; AMITRIPTYLINE; ANTICONVULSIVE AGENT; CARVEDILOL; CELECOXIB; CODEINE; CYTOCHROME P450; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; DIAZEPAM; GLIMEPIRIDE; IRBESARTAN; LOSARTAN; NORTRIPTYLINE; OMEPRAZOLE; OXYCODONE; PANTOPRAZOLE; SERTRALINE; TAMSULOSIN; WARFARIN; ZALTOPROFEN;

AGITATION; ARTICLE; ATAXIA; BLEEDING; BRADYCARDIA; BRONCHOSPASM; CAUCASIAN; CENTRAL NERVOUS SYSTEM DEPRESSION; CONFUSION; CONSTIPATION; DECISION MAKING; DIZZINESS; DROWSINESS; DRUG METABOLISM; GASTROINTESTINAL TOXICITY; GENETIC VARIABILITY; HALLUCINATION; HEADACHE; HEMATURIA; HUMAN; HYPERKALEMIA; HYPOGLYCEMIA; HYPOTENSION; HYPOTHERMIA; INDIVIDUALIZATION; INTESTINE CONTRACTION; KOREA; LETHARGY; MIOSIS; MUSCLE CRAMP; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; PATIENT MONITORING; PHARMACOGENETICS; PHENOTYPE; PRIORITY JOURNAL; RESPIRATION DEPRESSION; SEIZURE; SIDE EFFECT; SLURRED SPEECH; SOMNOLENCE; TACHYCARDIA; THROMBOCYTE DYSFUNCTION; TREMOR; URINE RETENTION; VASODILATATION; VOMITING;

EID: 33947102020     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp050490     Document Type: Article

References (62)

1. Veenstra DL, Higashi MK, Phillips KA. Assessing the cost-effectiveness of pharmacogenomics. AAPS PharmSci. 2000; 2: E29.
2. Flowers CR, Veenstra D. The role of cost-effectiveness analysis in the era of pharmacogenomics. Pharmacoeconomics. 2004; 22:481-93.
3. Margaret KM, Michael HW, Howard LM. Genetic basis of drug metabolism. Am J Health-Syst Pharm. 2002; 59:2061-9.
4. Evans WE, Relling MV. Pharmacogenomics: translating functional genomics into rational therapeutics. Science. 1999; 286:487-91.
5. Roden DM, George AL Jr. The genetic basis of variability in drug responses. Nat Rev Drug Discov. 2002; 1:37-44.
6. Evans WE, Relling MV. Moving towards individualized medicine with pharmacogenomics. Nature. 2004; 429:464-8.
7. Ensom MH, Chang TK, Patel P. Pharmacogenetics: the therapeutic drug monitoring of the future? Clin Pharmacokinet. 2001; 40:783-802.
8. Eap CB, Jaquenoud SE, Baumann P. Therapeutic monitoring of antidepressants in the era of pharmacogenetics studies. Ther Drug Monit. 2004; 26:152-5.
9. Leslie DJ. Pharmacogenomics: worthy of pharmacy's attention. Am J Health-Syst Pharm. 1999; 56:27. Editorial.
10. Roche Diagnostics. First chip-based test for broad diagnostic use in European Union has CE mark. The AmpliChip CYP450 test, www.roche.com/medcor- 2004-09-01 (accessed 2006 Oct 16).
11. Tina PB, Carmen MF, Dennis MW et al. Continuing-education programs in pharmacogenomics for pharmacists. Am J Health-Syst Pharm. 2002; 59:722-5.
12. Xie HG, Kim RB, Wood AJ et al. Molecular basis of ethnic differences in drug disposition and response. Annu Rev Pharmacol Toxicol. 2001; 41:815-50.
13. Wilkinson GR. Drug metabolism and variability among patients in drug response. N Engl J Med. 2005; 352:2211-21.
14. Daly AK, Brockmoller J, Broly F et al. Nomenclature for human CYP2D6 alleles. Pharmacogenetics. 1996; 6:193-201.
15. Human Cytochrome P450 (CYP) Allele Nomenclature Committee. Allele nomenclature for cytochrome P450 enzymes. www.imm.ki.se/CYPalleles (accessed 2006 Oct 16).
16. Indiana University School of Medicine. Drugs metabolized by cytochrome P-450. http://medicine.iupui.edu/flockhart/table.htm (accessed 2006 Oct 16).
17. Micromedex Healthcare Series. Vol. 125. Greenwood Village, CO: Thomson Micromedex; 2005.
18. Charles FL, Lora LA, Morton PG et al. Drug information handbook. 12th ed. Hudson, OH: Lexi-Comp; 2004.
19. Phillips KA, Veenstra DL, Oren E et al. Potential role of pharmacogenomics in reducing adverse drug reactions: a systematic review. JAMA. 2001; 286:2270-9.
20. Kirchheiner J, Brockmoller J. Clinical consequences of cytochrome P450 2C9 polymorphisms. Clin Pharmacol Ther. 2005; 77:1-16.
21. Yoon YR, Shon JH, Kim MK et al. Frequency of cytochrome P450 2C9 mutant alleles in a Korean population. Br J Clin Pharmacol. 2001; 51:277-80.
22. Bae JW, Kim HK, Kim JH et al. Allele and genotype frequencies of CYP2C9 in a Korean population. Br J Clin Pharmacol. 2005; 60:418-22.
23. Roh HK, Dahl ML, Tybring G et al. CYP2C19 genotype and phenotype determined by omeprazole in a Korean population. Pharmacogenetics. 1996; 6:547-51.
24. Xie HG, Stein CM, Kim RB et al. Allelic, genotypic, and phenotypic distribution of S-mephenytoin 4′-hydroxylase (CYP2C19) in healthy Caucasian populations of European descent throughout the world. Pharmacogenetics. 1999; 9:539-49.
25. Shin JG. Gene-environmental interactions in the disposition pharmacogenetics. Paper presented at the Second International Symposium on Pharmacogenomics. Seoul, Korea; 2005 Mar 18.
26. Gaedigk A, Gotschall RR, Forbes NS et al. Optimization of cytochrome P450 2D6 (CYP2D6) phenotype assignment using a genotyping algorithm based on allele frequency data. Pharmacogenetics. 1999; 9:669-82.
27. Yoon YR, Cha IJ, Shon JH et al. Relationship of paroxetine disposition to metoprolol metabolic ratio and CYP2D6*10 genotype of Korean subjects. Clin Pharmacol Ther. 2000; 67:567-76.
28. Roh HK, Dahl ML, Johansson I et al. Debrisoquine and S-mephenytoin hydroxylation phenotypes and genotypes in a Korean population. Pharmacogenetics. 1996; 6:441-7
29. Meyer UA. Pharmacogenetics-five decades of therapeutic lessons from genetic diversity. Nat Rev Genet. 2004; 5:669-76.
30. Dahl ML. Cytochrome P450 phenotyping/genotyping in patients receiving antipsychotics: useful aid to prescribing? Clin Pharmacokinet. 2002; 41:453-70.
31. Kirchheiner J, Bertilsson L, Bruus H et al. Individualized medicine-implementation of pharmacogenetic diagnostics in antidepressant drug treatment of major depressive disorders. Pharmacopsychiatry. 2003;36(suppl 3):S235-43.
32. Kubota T, Yamaura Y, Ohkawa N et al. Frequencies of CYP2D6 mutant alleles in a normal Japanese population and metabolic activity of dextromethorphan O-demethylation in different CYP2D6 genotypes. Br J Clin Pharmacol. 2000; 50:31-4.
33. Rogers JF, Nafziger AN, Bertino JS Jr. Pharmacogenetics affects dosing, efficacy, and toxicity of cytochrome P450-metabolized drugs. Am J Med. 2002; 113:746-50.
34. Yu KS, Cho JY, Jang IJ et al. Effect of the CYP3A5 genotype on the pharmacokinetics of intravenous midazolam during inhibited and induced metabolic states. Clin Pharmacol Ther. 2004; 76:104-12.
35. Kuehl P, Zhang J, Lin Y et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet. 2001; 27:383-91.
36. Shih PS, Huang JD. Pharmacokinetics of midazolam and 1-hydroxymidazolam in Chinese with different CYP3A5 genotypes. Drug Metab Dispos. 2002; 30:1491-6.
37. Floyd MD, Gervasini G, Masica AL et al. Genotype-phenotype associations for common CYP3A4 and CYP3A5 variants in the basal and induced metabolism of midazolam in European- and African-American men and women. Pharmacogenetics. 2003; 13:595-606.
38. Desta Z, Zhao X, Shin JG et al. Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin Pharmacokinet. 2002; 41:913-58.
39. McEvoy GK, ed. AHFS drug information. 47th ed. Bethesda, MD: American Society of Health-System Pharmacists; 2005.
40. Bort R, Ponsoda X, Carrasco E et al. Metabolism of aceclofenac in humans. Drug Metab Dispos. 1996; 24:834-41.
41. Furuta S, Akagawa N, Kamada E et al. Involvement of CYP2C9 and UGT2B7 in the metabolism of zaltoprofen, a nonsteroidal anti-inflammatory drug, and its lack of clinically significant CYP inhibition potential. Br J Clin Pharmacol. 2002; 54:295-303.
42. Niemi M, Cascori I, Timm R et al. Glyburide and glimepiride pharmacokinetics in subjects with different CYP2C9 genotypes. Clin Pharmacol Ther. 2002; 72:326-32.
43. Kobayashi K, Ishizuka T, Shimada N et al. Sertraline N-demethylation is catalyzed by multiple isoforms of human cytochrome P-450 in vitro. Drug Metab Dispos. 1999; 27:763-6.
44. Anderson IM. Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability. J Affect Disord. 2000; 58:19-36.
45. Steimer W, Muller B, Leucht S et al. Pharmacogenetics: a new diagnostic tool in the management of antidepressive drug therapy. Clin Chim Acta. 2001; 308:33-41.
46. Steimer W, Potter JM. Pharmacogenetic screening and therapeutic drugs. Clin Chim Acta. 2002; 315:137-55.
47. Meyer UA. Pharmacogenetics and adverse drug reactions. Lancet. 2000; 356:1667-71.
48. Aithal GP, Day CP, Kesteven PJ et al. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet. 1999; 353:717-9.
49. Higashi MK, Veenstra DL, Kondo LM et al. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA. 2002;287:1690-8.
50. Hillman MA, Wilke RA, Yale SH et al. A prospective, randomized pilot trial of model-based warfarin dose initiation using CYP2C9 genotype and clinical data. Clin Med Res. 2005; 3:137-45.
51. Aquilante CL, Langaee TY, Lopez LM et al. Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements. Clin Pharmacol Ther. 2006; 79:291-302.
52. Rieder MJ, Reiner AP, Gage BF et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med. 2005; 352:2285-93.
53. Holstein A, Plaschke A, Ptak M et al. Association between CYP2C9 slow metabolizer genotypes and severe hypoglycaemia on medication with sulphonylurea hypoglycaemic agents. Br J Clin Pharmacol. 2005;60:103-6.
54. Wan J, Xia H, He N et al. The elimination of diazepam in Chinese subjects is dependent on the mephenytoin oxidation phenotype. Br J Clin Pharmacol. 1996; 42:471-4.
55. Qin XP, Xie HG, Wang W et al. Effect of the gene dosage of CYP2C19 on diazepam metabolism in Chinese subjects. Clin Pharmacol Ther. 1999; 66:642-6.
56. Inomata S, Nagashima A, Itagaki F et al. CYP2C19 genotype affects diazepam pharmacokinetics and emergence from general anesthesia. Clin Pharmacol Ther. 2005; 78:647-55.
57. Dalen P, Dahl ML, Bernal Ruiz ML et al. 10-Hydroxylation of nortriptyline in white persons with 0,1,2, 3, and 13 functional CYP2D6 genes. Clin Pharmacol Ther. 1998; 63:444-52.
58. Yue QY, Zhong ZH, Tybring G et al. Pharmacokinetics of nortriptyline and its 10-hydroxy metabolite in Chinese subjects of different CYP2D6 genotypes. Clin Pharmacol Ther. 1998; 64:384-90.
59. Chen S, Chou WH, Blouin RA et al. The cytochrome P450 2D6 (CYP2D6) enzyme polymorphism: screening costs and influence on clinical outcomes in psychiatry. Clin Pharmacol Ther. 1996; 60:522-34.
60. Balant-Gorgia AE, Balant LP, Andreoli A. Pharmacokinetic optimisation of the treatment of psychosis. Clin Pharmacokinet. 1993; 25:217-36.
61. Dalen P, Frengell C, Dahl ML et al. Quick onset of severe abdominal pain after codeine in an ultrarapid metabolizer of debrisoquine. Ther Drug Monit. 1997; 19:543-4.
62. Gasche Y, Daali Y, Fathi M et al. Codeine intoxication associated with ultrarapid CYP2D6 metabolism. N Engl J Med. 2004; 351:2827-31.